FrancophonIA/ELRC3.0 huggingface dataset:
English: Xeristar is a medicine that contains the active substance duloxetine.
Estonian: Xeristar on ravim, mis sisaldab toimeainena duloksetiini.
English: For more information about treatment with Xeristar, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Xeristariga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Xeristar:
Estonian: Muu teave Xeristari kohta
English: Any patients taking Xeristar who have distressing thoughts or experiences at any time should tell their doctor immediately.
Estonian: Kui Xeristari kasutaval patsiendil tekivad mis tahes ajal rõhuvad mõtted või tunded, peab ta sellest teatama kohe arstile.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xeristar.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Xeristar must not be used together with monoamine oxidase inhibitors (another group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
Estonian: Xeristari ei tohi kasutada koos monoaminooksüdaasi inhibiitorite (teist liiki antidepressandid), fluvoksamiini (samuti antidepressant) ega tsiprofloksatsiini või enoksatsiiniga (antibiootikumide liigid).
English: Since these neurotransmitters are involved in maintaining high mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.
Estonian: Et need neurotransmitterid osalevad hea meeleolu säilitamises ja valutunde vähendamises, võib nende närvirakkudesse tagasihaarde pärssimine leevendada depressiooni, ärevuse ja neuropaatilise valu sümptomeid.
English: The other two studies looked at how long it took for symptoms to return in patients who had initially responded to Xeristar, including 288 patients with a history of repeated episodes of depression for up to five years.
Estonian: Ülejäänud kahes uuringus vaadeldi, mis aja jooksul sümptomid taastusid patsientidel, kellel oli esialgu tekkinud Xeristarile ravivastus, sealhulgas 288 patsiendil, kellel oli esinenud kuni viie aasta jooksul korduvaid depressiooniepisoode.
English: Patients who also have major depression should start with 60 mg once a day.
Estonian: Patsiendid, kellel on samuti raske depressioon, peavad alustama annusega 60 mg üks kord ööpäevas.
English: This document is a summary of the European Public Assessment Report (EPAR) for Xeristar.
Estonian: Käesolev dokument on ravimi Xeristar Euroopa avaliku hindamisaruande kokkuvõte.
English: Xeristar must also not be used in patients with certain types of liver disease or patients with severe kidney disease.
Estonian: Xeristari ei tohi kasutada ka patsiendid, kellel on teatud liiki maksahaigus või raske neeruhaigus.
English: Xeristar should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients.
Estonian: Xeristari ei tohi kasutada patsiendid, kes võivad olla duloksetiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The active substance in Xeristar, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Estonian: Xeristari toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor.
English: In the two studies where the approved dose of Xeristar was compared with placebo, Xeristar was more effective.
Estonian: Mõlemas uuringus, kus heakskiidetud annuses Xeristari võrreldi platseeboga, oli Xeristar efektiivsem.
English: For neuropathic pain, Xeristar has been compared with placebo in two 12-week studies in 809 diabetic adults.
Estonian: Neuropaatilise valu uuringus võrreldi Xeristari platseeboga kahes 12 nädalat kestnud uuringus, milles osales 809 diabeediga täiskasvanud patsienti.
English: Why has Xeristar been approved?
Estonian: Miks Xeristar heaks kiideti?
English: What is the risk associated with Xeristar?
Estonian: Mis riskid Xeristariga kaasnevad?
English: It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Estonian: See pärsib neurotransmitterite 5-hüdroksütrüptamiini (serotoniin) ja noradrenaliini tagasihaaret peaaju ja seljaaju närvirakkudesse.
English: For major depression, the recommended dose of Xeristar is 60 mg once a day.
Estonian: Raske depressiooni raviks on Xeristari soovituslik annus 60 mg üks kord ööpäevas.
English: Although the results of the depression studies varied, Xeristar was more effective than placebo in four of the studies.
Estonian: Kuigi depressiooniuuringute tulemused varieerusid, oli Xeristar efektiivsem kui platseebo neljas uuringus.
English: The dose of Xeristar should be reduced gradually when stopping treatment.
Estonian: Ravi katkestamisel tuleb Xeristari annust vähendada järk-järgult.
English: For the treatment of diabetic neuropathic pain, Xeristar was more effective at reducing pain than placebo.
Estonian: Diabeetilise neuropaatilise valu ravis vähendas Xeristar valu efektiivsemini kui platseebo.
English: In patients who respond to Xeristar, treatment should continue for several months, to prevent the disorder coming back.
Estonian: Patsiendid, kellel tekib Xeristarile ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist.
English: What is Xeristar?
Estonian: Mis on Xeristar?
English: As with other antidepressants, isolated cases of suicidal thoughts and behaviour have been seen in patients taking Xeristar, particularly in the first few weeks of treatment for depression.
Estonian: Nagu muudegi antidepressantide korral, on Xeristari kasutanud patsientidel täheldatud üksikjuhtudel suitsiidimõtteid ja suitsidaalset käitumist, eelkõige depressiooniravi algusnädalatel.
English: For generalised anxiety disorder, Xeristar has been compared with placebo in five studies involving a total of 2,337 patients.
Estonian: Generaliseerunud ärevushäire ravis võrreldi Xeristari platseeboga viies uuringus, milles osales kokku 2337 patsienti.
English: In patients who respond to Xeristar, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Estonian: Patsiendid, kellel tekib Xeristarile ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist; samuti peavad ravimi võtmist jätkama patsiendid, kellel on varem olnud korduvaid depressiooniepisoode.
English: For the full list of all side effects reported with Xeristar, see the Package Leaflet.
Estonian: Xeristari kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: For major depression, Xeristar has been compared with placebo (a dummy treatment) in eight main studies involving a total of 2,544 patients.
Estonian: Raske depressiooni uuringutes võrreldi Xeristari platseeboga (näiva ravimiga) kaheksas põhiuuringus, milles osales kokku 2544 patsienti.
English: The full EPAR for Xeristar can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Xeristari kohta on siin.
English: How is Xeristar used?
Estonian: Kuidas Xeristari kasutatakse?
English: What benefit has Xeristar shown during the studies?
Estonian: Milles seisneb uuringute põhjal Xeristari kasulikkus?
English: What is Xeristar used for?
Estonian: Milleks Xeristari kasutatakse?
English: It also took longer for symptoms to return in patients taking Xeristar than in those taking placebo.
Estonian: Xeristari saanud patsientidel kulus sümptomite taastumiseni rohkem aega kui platseebot saanud patsientidel.
English: The fifth study looked at how long it took for symptoms to return in 429 patients who had initially responded to Xeristar.
Estonian: Uuringus osales 429 patsienti, kellel oli esialgu tekkinud Xeristarile ravivastus.
English: For generalised anxiety disorder, Xeristar was also more effective than placebo at treating the disorder and preventing symptoms returning.
Estonian: Generaliseerunud ärevushäire korral oli Xeristar häire ravis ja haiguse taastumise ennetamisel samuti efektiivsem kui platseebo.
English: How has Xeristar been studied?
Estonian: Kuidas Xeristari uuriti?
English: How does Xeristar work?
Estonian: Kuidas Xeristar toimib?
English: London, 17 January 2008 EMEA/31266/2008
Estonian: London, 17. jaanuar 2008 EMEA/31266/2008
English: What is Zometa?
Estonian: Mis on Zometa?
English: If you are in a clinical trial and have any questions, contact your doctor.
Estonian: Kui osalete kliinilises uuringus ja teil on selle kohta küsimusi, võtke ühendust oma arstiga.
English: QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE APPLICATION FOR A CHANGE TO THE MARKETING AUTHORISATION for ZOMETA
Estonian: KÜSIMUSED JA VASTUSED MÜÜGILOA MUUTMISE TAOTLUSE TAGASIVÕTMISE KOHTA ZOMETA
English: International non-proprietary name (INN): zoledronic acid
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): zoledroonhape
English: The letter from the company notifying the EMEA of the withdrawal of the application is available here.
Estonian: Ettevõtte kiri, milles Euroopa Ravimiametit teavitati taotluse tagasivõtmisest, on esitatud siin.
English: This leads to less bone loss.
Estonian: Selle tulemusena väheneb luukadu.
English: The application was at day 90 when the company withdrew.
Estonian: Taotluse menetlemine oli kestnud 90 päeva, kui ettevõte taotluse tagasi võttis.
English: Following the CHMP's opinion, it usually takes around six weeks for the European Commission to update the licence.
Estonian: Pärast inimtervishoius kasutatavate ravimite komitee arvamust kulub Euroopa Komisjonil müügiloa pikendamiseks tavaliselt ligikaudu kuus nädalat.
English: The reduction of bone loss helps to make bones less likely to break, which may be useful in preventing fractures.
Estonian: Luukao vähenemisel väheneb luumurdude tõenäosus, mis võib aidata luumurde ennetada.
English: Aromatase inhibitors include anastrozole, letrozole and exemastane, and can cause bone loss and fractures as a side effect.
Estonian: Aromataasi inhibiitorid on anastrosool, letrosool ja eksemastaan ning luukoe vähenemine ja luumurrud võivad olla nende kõrvaltoimed.
English: The effectiveness of Zometa in preventing bone loss was studied in two main studies involving a total of 1,667 postmenopausal women treated for early-stage breast cancer with letrozole (an aromatase inhibitor).
Estonian: Zometa efektiivsust luukoe vähenemise ennetamisel uuriti kahes põhiuuringus, milles osales kokku 1667 varases staadiumis rinnavähiga menopausijärgses eas naist, keda raviti letrosooliga (aromataasi inhibiitor).
English: This includes fractures (broken bones), spinal compression (pressure on the spinal cord), bone disorders needing radiotherapy or surgery, and hypercalcaemia (high levels of calcium in the blood).
Estonian: Siia kuuluvad luumurrud, seljaaju kompressioon (kokkusurumine), kiiritusravi või kirurgilist ravi vajavad luuhäired ja hüperkaltseemia (vere kõrge kaltsiumitase).
English: Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Zometa had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Estonian: Seetõttu oli inimtervishoius kasutatavate ravimite komitee taotluse tagasivõtmise ajal seisukohal, et Zometa kasulikkus ei ole piisavalt tõendatud ning et selle võimalik kasulikkus ei ole suurem väljaselgitatud ohtudest.
English: Although Zometa seemed to reduce bone loss when it was started at the same time as letrozole, the CHMP was not convinced of the relevance of this finding in the absence of adequate information on fractures.
Estonian: Kuigi Zometa näis luukadu vähendavat, kui seda hakati kasutama letrosooliga samal ajal, ei olnud inimtervishoius kasutatavate ravimite komitee veendunud selle tulemuse asjakohasuses piisava teabe puudumise tõttu luumurdude kohta.
English: On 15 November 2007, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Zometa, in the prevention of fracture and bone loss in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors.
Estonian: 15. novembril 2007 teavitas Novartis Europharm Limited ametlikult inimtervishoius kasutatavate ravimite komiteed oma soovist võtta tagasi taotlus uue näidustuse lisamiseks Zometale luumurdude ja luukoe vähenemise ennetamiseks varases staadiumis rinnavähiga menopausijärgses eas naistel, keda ravitakse aromataasi inhibiitoritega.
English: What is happening for Zometa for the prevention of bone complications and hypercalcaemia?
Estonian: Kuidas mõjutab see Zometa kasutamist luutüsistuste ja hüperkaltseemia ennetamiseks?
English: This was not overcome by providing information on fractures from studies looking at Aclasta in the treatment of osteoporosis.
Estonian: Selle puuduse kõrvaldamiseks ei piisanud teabe esitamisest luumurdude kohta uuringutest, milles vaadeldi Aclasta kasutamist osteoporoosi ravis.
English: Bone mineral density was measured using a special type of X-ray called ‘dual energy X-ray absorptiometry' (DEXA).
Estonian: Luutihedust mõõdeti erilist tüüpi röntgenuuringuga, mida nimetatakse kahefootoniliseks röntgenabsorptsiomeetriaks (DEXA).
English: Zometa is a medicine containing the active substance zoledronic acid.
Estonian: Zometa on ravim, mis sisaldab toimeainena zoledroonhapet.
English: There are no consequences on the use of Zometa in its approved indications, for which the balance of benefits and risks remains positive.
Estonian: Zometa kasutamisele selle heakskiidetud näidustuseks, mille puhul ravimi kasulikkuse ja sellega seotud riskide suhe on endiselt positiivne, ei ole mitte mingeid tagajärgi.
English: The CHMP was also concerned that there was insufficient information to show that the dose of Zometa used in the studies was the most appropriate for these patients.
Estonian: Inimtervishoius kasutatavate ravimite komitee nägi põhjust ettevaatlikkuseks ka seetõttu, et ei olnud piisavalt teavet, mis tõendaks, et uuringutes kasutatud Zometa annus on neile patsientidele kõige sobivam.
English: Zometa can also be used to treat the hypercalcaemia caused by tumours.
Estonian: Zometat võib kasutada ka kasvajate põhjustatud hüperkaltseemia raviks.
English: After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues outstanding.
Estonian: Inimtervishoius kasutatavate ravimite komitee oli ettevõttele esitatud küsimuste vastused läbi vaadanud, kuid mõned küsimused olid veel lahendamata.
English: It is available as a powder and solvent to be made up into a solution for infusion (drip into a vein), and as a concentrate for infusion.
Estonian: Seda turustatakse pulbri ja lahustina, millest valmistatakse infusioonilahus (tilgutamiseks veeni), ning infusioonikontsentraadina.
English: How is Zometa expected to work?
Estonian: Milline on Zometa eeldatav toime?
English: Both studies looked at the effects of starting Zometa at the same time as starting letrozole treatment, compared with the effects of waiting until there was significant bone loss or evidence of a fracture before starting Zometa.
Estonian: Mõlemas uuringus vaadeldi Zometa toimet selle kasutamise alustamisel samaaegselt ravi alustamisega letrosooliga, võrreldes Zometa kasutamise alustamisega hiljem, mil luukude oli juba märkimisväärselt vähenenud või oli tekkinud luumurd.
English: What are the consequences of the withdrawal for patients in clinical trials using Zometa?
Estonian: Millised on taotluse tagasivõtmise tagajärjed praegu Zometa kliinilistes uuringutes osalevatele patsientidele?
English: It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Estonian: See pärsib osteoklastide, keha luukoe lagunemises osalevate rakkude aktiivsust.
English: The CHMP had concerns over the way the two main studies were designed, since they did not look directly at bone fractures.
Estonian: Inimtervishoius kasutatavate ravimite komitee nägi põhjust ettevaatlikkuseks kahe põhiuuringu ülesehituse tõttu, kuna neis ei vaadeldud otseselt luumurde.
English: This comparison was intended to provide information on the effect of zoledronic acid on bone fractures in women being treated with aromatase inhibitors.
Estonian: Selle võrdlusega kavatseti saada teavet zoledroonhappe toime kohta luumurdudele naistel, keda ravitakse aromataasi inhibiitoritega.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Zometa could not have been approved for the prevention of fractures and bone loss in women being treated with aromatase inhibitors.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimtervishoius kasutatavate ravimite komitee poolt esitatud küsimustele, nägi inimtervishoius kasutatavate ravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et Zometa kasutamist luumurdude ja luukoe vähenemise ennetamiseks naistel, keda ravitakse aromataasi inhibiitoritega, ei ole võimalik heaks kiita.
English: The active substance in Zometa, zoledronic acid, is a bisphosphonate.
Estonian: Zometas toimeainena sisalduv zoledroonhape on bifosfonaat.
English: Zometa is already approved for use in the prevention of bone complications in patients with advanced cancer that affects the bone.
Estonian: Zometa on juba heaks kiidetud luutüsistuste ennetamiseks kaugelearenenud, luud kahjustava vähiga patsientidel.
English: The main measure of effectiveness was the change in ‘bone mineral density' (the amount of bone) in the spine, between the start of the study and one year later.
Estonian: Efektiivsust mõõdeti põhiliselt selgroolülide luutiheduses ühe aasta möödumisel uuringu algusega võrreldes toimunud muutuse järgi.
English: The company informed the CHMP that this withdrawal does not have any effect on patients currently included in clinical trials with Zometa.
Estonian: Ettevõte teatas inimtervishoius kasutatavate ravimite komiteele, et sellel tagasivõtmisel ei ole Zometa kliinilistes uuringutes osalevatele patsientidele mitte mingeid tagajärgi.
English: In the new indication, Zometa was expected to be used to prevent fractures and bone loss in postmenopausal women with early-stage breast cancer who were being treated with anticancer medicines called aromatase inhibitors.
Estonian: Uue näidustuse puhul kavatseti Zometat kasutada luumurdude ja luukoe vähenemise ennetamiseks varases staadiumis rinnavähiga menopausijärgses eas naistel, keda ravitakse aromataasi inhibiitoritega.
English: The CHMP normally takes up to 90 days to adopt an opinion after it has received an application for a change to a marketing authorisation.
Estonian: Pärast taotluse saamist müügiloa muutmiseks kulub inimtervishoius kasutatavate ravimite komitee seisukoha vastuvõtmiseni tavaliselt kuni 90 päeva.
English: What was Zometa expected to be used for?
Estonian: Milleks kavatseti Zometat kasutada?
English: The company also compared the results of these studies with results from studies of Aclasta, another medicine that also contains zoledronic acid, but which is used to prevent fractures in postmenopausal women with osteoporosis.
Estonian: Nimetatud ravim sisaldab samuti zoledroonhapet, kuid seda kasutatakse osteoporoosiga menopausijärgses eas naiste raviks.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 13 March 2001
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA PIKENDAMISE KUUPÄEV 13. märts 2001
English: The recommended dose should not be exceeded.
Estonian: Soovitatavat annust ei tohi ületada.
English: Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands
Estonian: Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer Holland
English: Uxbridge UB9 6LS United Kingdom
Estonian: Uxbridge UB9 6LS Inglismaa
English: Administer to dogs within 1-2 hours after feeding.
Estonian: Manustada koertele 1 ... 2 tundi pärast söötmist.
English: Long term treatment should be under regular veterinary supervision.
Estonian: Pikaajaline ravi peab toimuma regulaarse veterinaarse jälgimise all.
English: After a treatment period of 7-10 days, the condition of the dog should be reevaluated in order to establish the need for continuation of treatment.
Estonian: Pärast 7-10 päeva pikkust raviperioodi tuleb koera seisundit uuesti hinnata, et teha kindlaks ravi jätkamise vajadus.
English: Each blister contains 10 oral lyophilisates.
Estonian: Igas blisterpakendis on 10 peroraalset lüofilisaati.
English: NAME OF THE MARKETING AUTHORISATION HOLDER Intervet International B. V.
Estonian: MÜÜGILOAHOIDJA Intervet International B. V.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Toimeaine
English: Monitor the hematocrit frequently.
Estonian: Mõõta sageli hematokritti.
English: MANUFACTURER'S BATCH NUMBER Batch {number}
Estonian: TOOTJAPOOLNE PARTII NUMBER Partii {number}
English: 1 box containing 1, 3 or 6 blisters.
Estonian: 1 karp mis sisaldab 1, 3 või 6 blistrit.
English: Pharmacotherapeutic group: Anti-inflammatory Products, Non Steroids ATCvet code: QM01AE92
Estonian: Farmakoterapeutiline grupp: mittesteroidsed põletikuvastased ained ATC vet kood: QM01AE92
English: 1 box containing 1 or 3 blisters.
Estonian: 1 karp mis sisaldab 1 või 3 blistrit.
English: If vomiting continues, administer anti-emetics.
Estonian: Kui oksendamine jätkub, manustada antiemeetikume.
English: In rare cases, particularly in older or in sensitive dogs, these undesirable effects may be serious or fatal.
Estonian: Harvadel juhtudel, peamiselt vanadel või ülitundlikel koertel, võivad kõrvalnähud olla tõsised ja põhjustada surma.
English: Use in animals less than 6 months of age, with a weight below 5 kg, or in aged animals, may involve additional risk.
Estonian: Kasutamine loomadel, kes on nooremad kui 6 kuud, kaaluvad vähem kui 5 kg või vanadel loomadel, võib preparaadi kasutamisega kaasneda lisarisk.
English: When this is not possible, or when dogs resist having the product placed directly into the mouth, put the tablet immediately before administration into a small amount of moistened food, or in a moist treat.
Estonian: Kui see ei ole võimalik või kui koer avaldab lüofilisaadi suhu manustamisel vastupanu, asetage lüofilisaat väikse koguse niiske sööda või maiustuse hulka.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti (EMA) koduleheküljelt aadressil http://www.ema.europa.eu..
English: Other NSAIDs, diuretics, anticoagulants and substances with high plasma protein binding may compete for binding leading to potentially toxic effects.
Estonian: Teised NSAID-id, diureetikumid, antikoagulandid ja kõrge plasma proteiinisiduvusega ained võivad konkureerida valgusiduvuse pärast ning see võib viia toksiliste toimete tekkimisele.
English: OTHER INFORMATION Not all pack sizes may be marketed.
Estonian: LISAINFO Kõik pakendi suurused ei pruugi olla müügil.
English: Push the bottom of the blister and the tablet will pop out.
Estonian: Vajutada blistri põhjale, ja lüofilisaat väljub blistrist.
English: If the oral lyophilisate disintegrates prematurely, wash hands thoroughly.
Estonian: Kui lüofilisaat on enneaegselt märgunud, pesta põhjalikult käed.
English: At a therapeutic dose of 10 mg/kg, the Cmax of tepoxalin was 1.08 ± 0.37 μg/ml in dogs fed a low fat meal and 1.19 ± 0.29 μg/ml in dogs fed a high fat meal.
Estonian: Terapeutilise annuse 10 mg/kg korral oli Cmax vähese rasvasusega söödaga manustades 1,08 ± 0,37 μg/ml, suure rasvasusega söödaga manustamisel aga 1,19 ± 0.29 μg/ml.